MX2012008801A - Composiciones farmaceuticas para el tratamiento de dolor y otras indicaciones. - Google Patents
Composiciones farmaceuticas para el tratamiento de dolor y otras indicaciones.Info
- Publication number
- MX2012008801A MX2012008801A MX2012008801A MX2012008801A MX2012008801A MX 2012008801 A MX2012008801 A MX 2012008801A MX 2012008801 A MX2012008801 A MX 2012008801A MX 2012008801 A MX2012008801 A MX 2012008801A MX 2012008801 A MX2012008801 A MX 2012008801A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- pain
- disease
- compositions
- disorder
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000003940 fatty acid amidase inhibitor Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 102100027297 Fatty acid 2-hydroxylase Human genes 0.000 abstract 1
- 208000001640 Fibromyalgia Diseases 0.000 abstract 1
- 101000937693 Homo sapiens Fatty acid 2-hydroxylase Proteins 0.000 abstract 1
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000001294 Nociceptive Pain Diseases 0.000 abstract 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 abstract 1
- 229960004945 etoricoxib Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000020685 sleep-wake disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29908710P | 2010-01-28 | 2010-01-28 | |
| PCT/US2011/022412 WO2011094209A1 (en) | 2010-01-28 | 2011-01-25 | Pharmaceutical compositions for the treatment of pain and other indicatons |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012008801A true MX2012008801A (es) | 2012-08-17 |
Family
ID=44319717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012008801A MX2012008801A (es) | 2010-01-28 | 2011-01-25 | Composiciones farmaceuticas para el tratamiento de dolor y otras indicaciones. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130030000A1 (OSRAM) |
| EP (1) | EP2528603A4 (OSRAM) |
| JP (1) | JP2013518110A (OSRAM) |
| KR (1) | KR20120123691A (OSRAM) |
| CN (1) | CN102858338A (OSRAM) |
| AU (1) | AU2011209754A1 (OSRAM) |
| BR (1) | BR112012018913A2 (OSRAM) |
| CA (1) | CA2786888A1 (OSRAM) |
| MX (1) | MX2012008801A (OSRAM) |
| RU (1) | RU2012136624A (OSRAM) |
| WO (1) | WO2011094209A1 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2732526A1 (en) * | 2008-08-04 | 2010-02-11 | Merck Sharp & Dohme Corp. | Oxazole derivatives useful as inhibitors of faah |
| AU2011238487B2 (en) * | 2010-04-08 | 2015-10-01 | Merck Sharp & Dohme Corp. | Oxazole derivatives useful as modulators of FAAH |
| WO2011133444A1 (en) | 2010-04-21 | 2011-10-27 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| EP2582373A4 (en) | 2010-06-16 | 2013-10-30 | Bruce Chandler May | USE OF LEVOCETIRIZIN AND MONTELUKAST IN THE TREATMENT OF INFLUENZA, COLLECTIONS AND INFLAMMATION |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| WO2014164285A2 (en) | 2013-03-13 | 2014-10-09 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of vasculitis |
| ES2660494T3 (es) | 2013-03-13 | 2018-03-22 | 14779507 | Uso de levocetirizina y montelukast en el tratamiento de una lesión traumática |
| CA2901421A1 (en) | 2013-03-13 | 2014-10-09 | Bruce Chandler May | Use of levocetirizine and montelukast in the treatment of autoimmune disorders |
| JP6483666B2 (ja) | 2013-10-14 | 2019-03-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 選択的に置換されたキノリン化合物 |
| WO2015057659A1 (en) | 2013-10-14 | 2015-04-23 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
| PL3077047T3 (pl) * | 2013-12-04 | 2019-10-31 | Galmed Res & Development Ltd | Sole aramcholu |
| WO2016036588A1 (en) * | 2014-09-03 | 2016-03-10 | Merck Sharp & Dohme Corp. | Pharmaceutical suspensions containing etoricoxib |
| EP3193875B1 (en) | 2014-09-15 | 2022-02-16 | Inflammatory Response Research, Inc. | Levocetirizine and montelukast in the treatment of inflammation mediated conditions |
| PL3595665T3 (pl) * | 2017-03-13 | 2025-01-13 | Lundbeck La Jolla Research Center, Inc. | Podwójne inhibitory magl i faah |
| WO2019008115A1 (en) | 2017-07-07 | 2019-01-10 | Syngenta Participations Ag | HETEROCYCLIC DERIVATIVES HAVING PESTICIDE ACTIVITY HAVING SUBSTITUENTS CONTAINING SULFUR |
| KR102257685B1 (ko) | 2018-09-20 | 2021-05-31 | 성균관대학교산학협력단 | Cox-2 억제제를 유효성분으로 포함하는 소염진통 예방 또는 치료용 정제 조성물 |
| CN110156710B (zh) * | 2019-04-30 | 2022-10-28 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 一种多取代噁唑类化合物的制备方法 |
| JP7464955B2 (ja) | 2020-02-27 | 2024-04-10 | 国立大学法人千葉大学 | ヨードオキサゾール化合物の製造方法、オキサゾール化合物の製造方法 |
| WO2021236518A1 (en) * | 2020-05-19 | 2021-11-25 | IRR, Inc. | Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof |
| WO2022251707A1 (en) * | 2021-05-28 | 2022-12-01 | Ananda Scientific, Inc. | Methods for the treatment of post-traumatic stress disorder and traumatic brain injury with cannabinoids |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA008767B1 (ru) * | 2002-10-08 | 2007-08-31 | Зе Скрипс Ресеч Инститьют | Ингибиторы гидролазы амидов жирных кислот |
| HRP20150765T1 (hr) * | 2004-12-30 | 2015-10-09 | Janssen Pharmaceutica N.V. | Amid derivati piperidin- i piperazin-1-karboksilne kiseline te povezani spojevi kao modulatori amid hidrolaze masnih kiselina (faah) za lijeäśenje tjeskobe, boli i drugih stanja |
| EP1866293A1 (en) * | 2005-03-31 | 2007-12-19 | UCB Pharma, S.A. | Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses |
| AU2008257154B2 (en) * | 2007-05-25 | 2014-03-06 | The Scripps Research Institute | Tetracyclic inhibitors of fatty acid amide hydrolase |
| JP2011523959A (ja) * | 2008-06-11 | 2011-08-25 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｆａａｈの阻害剤として有用なイミダゾール誘導体 |
| JP2011524872A (ja) * | 2008-06-11 | 2011-09-08 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｆａａｈの阻害剤として有用なピラゾール誘導体 |
| CA2732526A1 (en) * | 2008-08-04 | 2010-02-11 | Merck Sharp & Dohme Corp. | Oxazole derivatives useful as inhibitors of faah |
-
2011
- 2011-01-25 CN CN2011800171616A patent/CN102858338A/zh active Pending
- 2011-01-25 EP EP11737514.7A patent/EP2528603A4/en not_active Withdrawn
- 2011-01-25 US US13/574,303 patent/US20130030000A1/en not_active Abandoned
- 2011-01-25 RU RU2012136624/15A patent/RU2012136624A/ru not_active Application Discontinuation
- 2011-01-25 WO PCT/US2011/022412 patent/WO2011094209A1/en not_active Ceased
- 2011-01-25 KR KR1020127022379A patent/KR20120123691A/ko not_active Withdrawn
- 2011-01-25 JP JP2012551232A patent/JP2013518110A/ja not_active Withdrawn
- 2011-01-25 MX MX2012008801A patent/MX2012008801A/es not_active Application Discontinuation
- 2011-01-25 AU AU2011209754A patent/AU2011209754A1/en not_active Abandoned
- 2011-01-25 CA CA2786888A patent/CA2786888A1/en not_active Abandoned
- 2011-01-25 BR BR112012018913A patent/BR112012018913A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN102858338A (zh) | 2013-01-02 |
| EP2528603A4 (en) | 2013-09-04 |
| EP2528603A1 (en) | 2012-12-05 |
| RU2012136624A (ru) | 2014-03-10 |
| BR112012018913A2 (pt) | 2017-06-20 |
| US20130030000A1 (en) | 2013-01-31 |
| AU2011209754A1 (en) | 2012-07-26 |
| CA2786888A1 (en) | 2011-08-04 |
| WO2011094209A1 (en) | 2011-08-04 |
| JP2013518110A (ja) | 2013-05-20 |
| KR20120123691A (ko) | 2012-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012008801A (es) | Composiciones farmaceuticas para el tratamiento de dolor y otras indicaciones. | |
| MX340441B (es) | Proceso para tratar fibras queratinicas alaciadas. | |
| EA019744B9 (ru) | Изотиазолилоксифениламидины и их применение для борьбы с фитопатогенными грибами и семенной материал, обработанный изотиазолилоксифениламидинами | |
| PH12016500216B1 (en) | Stable pharmaceutical composition and methods of using same | |
| MY153948A (en) | Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof | |
| EP2593102A4 (en) | OXAZOLE DERIVATIVES SUITABLE AS FAAH MODULATORS | |
| PH12014502775A1 (en) | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | |
| MX341110B (es) | Inhibidores de la amida hidrolasa de acidos grasos (faah). | |
| GEP20146197B (en) | New compounds | |
| IN2012DN01434A (OSRAM) | ||
| MX2015015416A (es) | Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos. | |
| BR112014003602A2 (pt) | método para a produção de um sal de metionina | |
| GEP20196969B (en) | New therapeutical composition containing apomorphine as active ingredient | |
| MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
| IN2012DN05192A (OSRAM) | ||
| PH12014502805A1 (en) | Novel indanesulfamide derivative | |
| UA110807C2 (uk) | КРИСТАЛІЧНІ ФОРМИ ГІДРОХЛОРИДУ (4A-R,9A-S)-1-(1H-БЕНЗОІМІДАЗОЛ-5-КАРБОНІЛ)-2,3,4,4А,9,9А-ГЕКСАГІДРО-1H-ІНДЕНО[2,1-b]ПІРИДИН-6-КАРБОНІТРИЛУ ТА ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ HSD 1 | |
| MX340883B (es) | Emulsiones de poliisobutenos, sustancia y proceso. | |
| EA201400210A1 (ru) | Применение и агрохимическая композиция дибутиламидов карбоновой кислоты | |
| BR112012028055A2 (pt) | composto, uso do mesmo, composição farmacêutica, e, métodos de tratar uma doença mediada | |
| PH12013500371A1 (en) | Therapeutic agent for pain | |
| EP2557938A4 (en) | PROTECTED ALPHA AMYLASE | |
| MX336477B (es) | Derivado de aminoacido. | |
| MX2011009224A (es) | Derivados de imidazol utiles como modulares de amida hidrolasa de acido graso y como agentes de formacion de imagenes de amida hidrolasa de cido graso. | |
| MX2013002485A (es) | Fenilacetamidas y fenilpropanamidas sustituidas y su uso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |